Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.
News|Articles|April 15, 2014
- Pharmaceutical Technology-04-15-2014
- Volume 2014 eBook
- Issue 1
Controlled-Release Technologies Create Opportunities for Solid-Dosage Drug Formulators
Author(s)Cynthia A. Challener
Lifecycle management opportunities are impacting the development of controlled-release technologies for solid-dosage drugs.
Advertisement
Lifecycle management opportunities including clinical and compliance benefits coupled with the need for patent extensions are impacting the development of controlled-release technologies for solid-dosage drugs.
Download
.
Articles in this issue
over 12 years ago
Continuous Manufacturing for Solid-Dosage Drug Productionover 12 years ago
Using Modular Systems in Solid-Dosage Manufacturingover 12 years ago
Advances in Hot-Melt Extrusion Manufacturingover 12 years ago
Selection of Excipients in Generic FormulationsAdvertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
What the Olanzapine Depot Approval Means for CMC Teams
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
Q&A: Patient-Centric Drug Development Should Start at Product Definition
4
PharmTech Weekly Roundup—Oct. 8, 2026: CPHI Highlights
5